In the initial phase, this study recruited 9 HLH patients who showed hematological evidence of disease progression while receiving dexamethasone and cyclosporine in combination with anti‐CD41‐PLT‐VP16 treatment (Table S1, Supporting Information). This evidence concerns the gene NAAA and hemophagocytic syndrome.